# Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

> **NCT00581425** · PHASE4 · COMPLETED · sponsor: **The University of Texas Health Science Center, Houston** · enrollment: 49 (actual)

## Conditions studied

- Basal Cell Carcinoma

## Interventions

- **BIOLOGICAL:** Imiquimod and Interferon alpha

## Key facts

- **NCT ID:** NCT00581425
- **Lead sponsor:** The University of Texas Health Science Center, Houston
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2013-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00581425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00581425, "Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT00581425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*